Advanced therapy medicinal products (ATMPs) are the cutting edge of drug innovation. ATMPs have different challenges than other drug classes. To accommodate these challenges and facilitate science-driven development, flexibility in the requirements to demonstrate the safety and efficacy of this rapidly evolving drug class is necessary. To create flexibility, the European Union introduced the risk-based approach. This approach provides the possibility of omitting guideline-based studies based on risk analyses. To gain insight into the effect of the risk-based approach on the non-clinical development of ATMPs, two questions are addressed in this paper. Firstly, "Do companies use a risk-based approach for the non-clinical development of ATMPs?" and, secondly, "Does the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) accept non-clinical development programs based on the risk-based approach?" Scientific advice letters formulated by the CHMP were analyzed. The risk-based approach was used to justify deviations from the guidelines in the majority (75%) of the cases. The CHMP accepted 40% of the proposals to omit studies and stated that additional data was necessary to make an informed decision for 35% of the proposals. This indicates that the risk-based approach facilitates the science-driven development of ATMPs.
[1]
Spiros Vamvakas,et al.
On the edge of new technologies (advanced therapies, nanomedicines).
,
2011,
Drug discovery today. Technologies.
[2]
M. Carr,et al.
Regulatory structures for gene therapy medicinal products in the European Union.
,
2012,
Methods in enzymology.
[3]
Robert Zorec,et al.
Challenges with advanced therapy medicinal products and how to meet them
,
2010,
Nature Reviews Drug Discovery.
[4]
Fulvio Mavilio,et al.
Gene therapies need new development models
,
2012,
Nature.
[5]
Andrew Buchanan,et al.
Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive.
,
2012,
Molecular therapy : the journal of the American Society of Gene Therapy.